Roche’s giredestrant FDA review raises the stakes in adjuvant breast cancer treatment
Find out how Roche’s giredestrant FDA priority review could reshape endocrine therapy in early breast cancer.
Pharma & Biotech
Pharma & Biotech
Genentech’s ASCO 2026 data puts giredestrant at the centre of Roche’s breast cancer strategy
Endocrine therapy is crowded. Genentech needs giredestrant to prove it can shift breast cancer care, not just add another option.
Pharma & Biotech
Why the MiRaDoR study may redefine therapeutic timing in HR+/HER2- patients
Natera Inc. and Medica Scientia Innovation Research (MEDSIR) have announced a collaborative effort on the MiRaDoR study, a multicenter, phase II clinical trial focused on hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. Sponsored by MEDSIR and funded by F. Hoffmann-La Roche Ltd., the trial uses Natera’s Signatera assay to guide therapy decisions based on circulating tumor